Hepion pharmaceuticals executes binding letter of intent with new day diagnostics to commercialize diagnostic tests for celiac disease, respiratory multiplex, h. pylori and hcc

Morristown, n.j., may 07, 2025 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic liver diseases, today announced that it has entered into a binding letter of intent (“loi”) with new day diagnostics llc to in-license diagnostic tests for celiac disease, respiratory multiplex (covid/influenza a/b and rsv), helicobacter pylori (h. pylori) and hepatocellular carcinoma (hcc). the celiac, respiratory multiplex and h. pylori tests have ce marks and are eligible to be sold in europe at the present time.
HCC Ratings Summary
HCC Quant Ranking